5-(4-chlorophenyl)-5-oxo-3-phenylpentanoic acid | 77565-60-7

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物
• 英文名称: 5-(4-chlorophenyl)-5-oxo-3-phenylpentanoic acid
• CAS: 77565-60-7
• 化学式: C₁₇H₁₅ClO₃
• 分子量: 302.757
• InChiKey: GOIDVUGVVBKWDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(4-chlorophenyl)-5-oxo-3-phenylpentanoic acid 在 sodium tetrahydroborate 、 盐酸羟胺 、 sodium acetate 、 nickel dichloride 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 15.0h， 生成 trans-6(4-chlorophenyl)-4-phenyl-2-piperidone
  参考文献：
  名称：

  Rao, H. Surya Prakash; Bharathi, B., Journal of Chemical Research, Miniprint, 1994, # 3, p. 541 - 554

  摘要：

  DOI：
• 作为产物：
  描述：

  (2E)-1-(4-氯苯基)-3-苯基-2-丙烯-1-酮 在 甲醇 、 barium dihydroxide 、 氢氧化钾 、 乙醇 作用下， 反应 1.0h， 生成 5-(4-chlorophenyl)-5-oxo-3-phenylpentanoic acid
  参考文献：
  名称：

  Rao, H. Surya Prakash; Bharathi, B., Journal of Chemical Research, Miniprint, 1994, # 3, p. 541 - 554

  摘要：

  DOI：

文献信息

• [EN] ALLOSTERIC PROTEIN KINASE MODULATORS<br/>[FR] MODULATEURS DE PROTÉINE KINASE ALLOSTÉRIQUE
  申请人：UNIV SAARLAND

  公开号：WO2010043711A1

  公开（公告）日：2010-04-22

  The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

  该发明提供特定的小分子化合物，这些化合物能够变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白-蛋白相互作用，提供这些化合物的制备方法，包含这些化合物的药物组合物，以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
• ALLOSTERIC PROTEIN KINASE MODULATORS
  申请人：Engel Matthias

  公开号：US20120046307A1

  公开（公告）日：2012-02-23

  The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

  本发明提供了特定的小分子化合物，它们通过变构调节AGC蛋白激酶的活性或调节Aurora家族蛋白激酶的蛋白质-蛋白质相互作用，其生产方法，包含该化合物的药物组合物，以及它们用于制备治疗和预防与AGC蛋白激酶或Aurora家族蛋白激酶异常活动相关疾病的药物的应用。
• Regioselective installation of enolizable ketones and unprotected mercaptoacetic acid into olefins using GO as a phase transfer catalyst
  作者：Prashant Shukla、Manorama Singh、Vijai K. Rai、Ankita Rai

  DOI：10.1039/d1nj05870c

  日期：——

  We report herein an unprecedented conjugate addition of enolizable ketones and unprotected mercaptoacetic acid to electron-poor alkenes using graphene oxide as a phase transfer catalyst. The envisaged protocol is versatile and applicable to structurally different Michael acceptors such as α,β-unsaturated aldehyde/ketone/acid/ester/amide/nitrile, and β-nitroalkene to afford their corresponding adducts

  我们在此报道了使用氧化石墨烯作为相转移催化剂，将烯醇化酮和未保护的巯基乙酸与缺电子烯烃的前所未有的共轭加成。设想的协议是通用的，适用于结构不同的迈克尔受体，如 α、β-不饱和醛/酮/酸/酯/酰胺/腈和 β-硝基烯烃，以提供相应的加合物。产品操作简单的区域选择性、环境反应条件、优异的产品产率（高达 92%）和催化剂的可回收性高达五次而形态没有任何实质性变化以及催化效率是所设想协议的显着特征.
• Allosteric protein kinase modulators
  申请人：Engel Matthias

  公开号：US08912186B2

  公开（公告）日：2014-12-16

  The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

  本发明提供了一种特定的小分子化合物，可以变构地调节AGC蛋白激酶和Aurora家族蛋白激酶的活性或调节它们之间的蛋白质相互作用，以及制备它们的方法、包含它们的制药组合物，以及它们用于制备治疗与AGC蛋白激酶或Aurora家族蛋白激酶异常活性相关的疾病的药物。
• 2-(3-Oxo-1,3-diphenylpropyl)malonic Acids as Potent Allosteric Ligands of the PIF Pocket of Phosphoinositide-Dependent Kinase-1: Development and Prodrug Concept
  作者：Adriana Wilhelm、Laura A. Lopez-Garcia、Katrien Busschots、Wolfgang Fröhner、Frauke Maurer、Stefan Boettcher、Hua Zhang、Jörg O. Schulze、Ricardo M. Biondi、Matthias Engel

  DOI：10.1021/jm3010477

  日期：2012.11.26

  The protein kinase C-related kinase 2 (PRK2)interacting fragment (PIF) pocket of phosphoinositide-dependent kinase-1 (PDK1) was proposed as a novel target site for allosteric modulators. In the present work, We describe the design, synthesis, and structure-activity relationship of a series of 2-(3-oxo-1,3- diphenylprapyl)malonic acids as potent allosteric activators binding, to the PIF pocket: Some congeners displayed AC(50) values for PDK1 activation in the submicromolar range. The potency of the best compounds to stabilize PDK1 in a thermal stability shift assay was in the same order Of magnitude as that of the PIF pocket binding peptide PIFtide, suggesting comparable binding affinities to the pm pocket, The crystal structure of PDK1 in complex with compound 4h revealed that additional ionic interactions are mainly responsible for the increased potency compared to the monocarboxylate analogues. Notably, several compounds displayed high selectivity for PDK1 Employing a prodrug strategy, we were able to corrroborate the novel mechanism of action in cells.